Arkolith/Insider Trading/ZIVO/Form 4

Marchiando Keith

Chief Financial OfficerZivo Bioscience, Inc. (ZIVO) · full profile →Form 4 · filed Jun 6, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
0 non-derivative · 4 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 5, 2024Disposed to issuer(D)48K——0
Jun 5, 2024Disposed to issuer(D)10K——0
Jun 5, 2024Disposed to issuer(D)27K——0
Jun 5, 2024Grant(A)444K——444K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001654954-24-007461) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML